Global regulators, industry leaders, scientists, and patient advocates set near-term commitments on early interception, trial modernization, and patient-first evidence.Continue reading
Author Archive: Roxan Olivas
C-Path’s Translational Therapeutics Accelerator Marks Record Year with Seven BRIDGe Awards Advancing Potential Therapies Across Cancer, Infectious Disease, Neurology and Immunology
Program launched in 2022 has grown into a global pipeline partner for academic teams, awarding approximately $2.48 million in 2025 to projects in the U.S., Europe and AustraliaContinue reading
Join Global Leaders in Shaping the Future of Drug Development at C-Path’s 2025 Global Impact Conference
Every Stage, Every Step: Transforming Lives Through Optimized Drug DevelopmentContinue reading
Critical Path Institute Appoints Dr. Aoife Brennan to Board of Directors
TUCSON, Ariz., July 16, 2025 — Critical Path Institute® (C-Path) today announced the appointment of Aoife Brennan, M.D., to its Board of Directors. Dr. Brennan brings extensive experience in biopharmaceutical leadership, clinical development, and regulatory strategy to C-Path’s growing efforts to advance global drug development and data-driven science.Continue reading
C-Path’s Translational Therapeutics Accelerator Announces $200,000 Grant for Drug Development Project in Inflammatory Bowel Disease
University Hospitals Cleveland Medical Center physician awarded funding to advance novel therapy for IBD.Continue reading
C-Path’s Kristen Swingle Named a “Woman Leading the Region” by BizTucson
TUCSON, Ariz., July 9, 2025 — Critical Path Institute® (C-Path) is proud to announce that President and Chief Operating Officer Kristen Swingle, M.S., has been named a 2025 BizTucson “Woman Leading the Region,” an honor recognizing Southern Arizona’s most impactful women in leadership, innovation, and community advancement. Continue reading
C-Path’s Translational Therapeutics Accelerator Announces New Grant Award for Drug Development Project in Type 1 Diabetes
TUCSON, Ariz., June 18, 2025 — Critical Path Institute’s® (C-Path) Translational Therapeutics Accelerator (TRxA) proudly announced today a $250,000 grant award aimed at developing a novel treatment for type 1 diabetes (T1D). Continue reading
Critical Path Institute and Citizen Health Partner to Accelerate Drug Development for Neuromuscular Disorders
SAN FRANCISCO and TUCSON, Ariz., May 29, 2025 — Critical Path Institute® (C-Path), a global nonprofit accelerating drug development through data science and regulatory innovation, and Citizen Health, a leading consumer health platform, today announced their new strategic collaboration. Together, the organizations will establish a partnership focused on neuromuscular disorders, including limb-girdle muscular dystrophies (LGMDs), Charcot-Marie-Tooth (CMT) disease, nemaline myopathy (NM), myotonic dystrophies, and related conditions.Continue reading
Critical Path Institute Celebrates 20 Years of Advancing Drug Development through Innovation and Collaboration
TUCSON, Ariz., May 8, 2025 — The year 2025 marks a historic milestone for Critical Path Institute® (C-Path), as the organization celebrates 20 years of transforming the landscape of drug development through collaboration, regulatory science, and next-generation strategies. Continue reading